Insights and updates on mass torts, legal intake, and marketing strategies for law firms.https://masstortstrategies.com/https://masstortstrategies.com/tepezza-lawsuit-updates/https://masstortstrategies.com/tepezza-lawsuit-updates/Tepezza, a medication approved by the FDA in 2020 for the treatment of Thyroid Eye Disease (TED), has recently come under scrutiny due to reports linking it to hearing-related side effects, including hearing loss and tinnitus. These developments have led to a series of lawsuits against the manufacturer, Horizon Therapeutics, alleging failure to adequately warnFri, 07 Mar 2025 09:00:00 GMThttps://masstortstrategies.com/eaton-fire-lawsuit-updates/https://masstortstrategies.com/eaton-fire-lawsuit-updates/The Eaton Fire has become one of the most devastating wildfires in recent California history, leaving destruction and legal uncertainty in its wake. The fire began on January 7, 2025, near electrical towers in Eaton Canyon, rapidly spreading across 14,117 acres in Altadena, California. With only 33% containment, the fire has tragically claimed 17 lives,Wed, 05 Mar 2025 14:30:36 GMThttps://masstortstrategies.com/the-mts-process-transforming-claimant-acquisition-for-law-firms/https://masstortstrategies.com/the-mts-process-transforming-claimant-acquisition-for-law-firms/At Mass Tort Strategies (MTS), our mission is clear: to simplify the claimant acquisition process while delivering high-quality, signed retainers to our law firm partners. We understand the challenges attorneys face with traditional lead generation, which often results in unqualified leads and wasted resources. That’s why we’ve developed a streamlined, compliance-driven process designed to maximizeFri, 10 Jan 2025 11:59:04 GMThttps://masstortstrategies.com/mts-2024-performance-highlights/https://masstortstrategies.com/mts-2024-performance-highlights/As we reflect on 2024, we’re proud to celebrate an incredible year of growth, impact, and success at Mass Tort Strategies (MTS). Thanks to the dedication of our skilled intake team and strong partnerships with law firms, we’ve achieved remarkable milestones in delivering high-quality, responsive cases to our partners. Here’s what we accomplished in 2024:Fri, 10 Jan 2025 11:33:22 GMThttps://masstortstrategies.com/key-factors-to-consider-when-evaluating-a-mass-tort/https://masstortstrategies.com/key-factors-to-consider-when-evaluating-a-mass-tort/Mass torts represent a strategic opportunity for law firms to expand their practice and achieve significant revenue growth. However, these complex cases require careful evaluation to ensure a successful outcome. At MTS, we specialize in helping firms navigate the intricacies of mass tort litigation, from intake to settlement. Below, we break down seven critical factorsFri, 10 Jan 2025 11:25:09 GMThttps://masstortstrategies.com/national-trial-lawyers-summit-miami-2025/https://masstortstrategies.com/national-trial-lawyers-summit-miami-2025/Connect with MTS at the National Trial Lawyers Summit in Miami The Mass Tort Strategies (MTS) management team is excited to announce our participation in the upcoming National Trial Lawyers (NTL) Summit, scheduled for January 26-30, 2025, at the prestigious Loews Miami Beach Hotel in Miami, Florida. About the NTL Summit The NTL Summit isWed, 08 Jan 2025 12:02:02 GMThttps://masstortstrategies.com/nec-lawsuit-updates/https://masstortstrategies.com/nec-lawsuit-updates/Necrotizing enterocolitis (NEC) is a severe gastrointestinal condition predominantly affecting premature infants. Recent legal actions have targeted manufacturers of cow’s milk-based infant formulas, alleging a link between these products and an increased risk of NEC in preterm babies. As of December 2024, significant developments have emerged in this mass tort litigation, impacting both affected familiesFri, 27 Dec 2024 15:29:15 GMThttps://masstortstrategies.com/oxbryta-lawsuit-updates/https://masstortstrategies.com/oxbryta-lawsuit-updates/Oxbryta (voxelotor), a medication developed to treat sickle cell disease (SCD), has recently become the focus of significant legal action following its global recall in September 2024. Manufactured by Pfizer, Oxbryta was initially hailed as a breakthrough treatment for SCD, a genetic disorder characterized by abnormal hemoglobin that leads to distorted, sickle-shaped red blood cells.Fri, 27 Dec 2024 14:28:04 GMThttps://masstortstrategies.com/fccs-one-to-one-consent-a-game-changer-for-law-firm-marketing/https://masstortstrategies.com/fccs-one-to-one-consent-a-game-changer-for-law-firm-marketing/The legal marketing landscape is about to transform significantly. On January 27, 2025, the Federal Communications Commission (FCC) will enforce the One-to-One Consent Rule under the Telephone Consumer Protection Act (TCPA). This groundbreaking regulation introduces strict guidelines on how businesses, including law firms, communicate with potential clients. For law firms relying on lead generation, understandingFri, 27 Dec 2024 14:00:08 GMThttps://masstortstrategies.com/depo-provera-lawsuit-updates/https://masstortstrategies.com/depo-provera-lawsuit-updates/Depo-Provera, a widely used injectable contraceptive, has recently come under legal scrutiny due to allegations linking its prolonged use to the development of intracranial meningiomas—benign brain tumors arising from the meninges, the protective layers surrounding the brain and spinal cord. As of December 2024, numerous lawsuits have been filed against Pfizer, the manufacturer of Depo-Provera,Fri, 27 Dec 2024 13:42:56 GMThttps://masstortstrategies.com/selecting-a-mass-tort-marketing-partner-7-key-questions-to-ensure-success/https://masstortstrategies.com/selecting-a-mass-tort-marketing-partner-7-key-questions-to-ensure-success/Expanding into mass tort litigation offers law firms significant revenue opportunities. However, achieving success in this complex field requires more than legal expertise; it demands strategic marketing acumen and resources. Partnering with a specialized mass tort marketing firm can provide the necessary support, but selecting the right partner is crucial. Here are seven essential questionsFri, 27 Dec 2024 10:36:23 GMT